JP2011526249A5 - - Google Patents

Download PDF

Info

Publication number
JP2011526249A5
JP2011526249A5 JP2011515029A JP2011515029A JP2011526249A5 JP 2011526249 A5 JP2011526249 A5 JP 2011526249A5 JP 2011515029 A JP2011515029 A JP 2011515029A JP 2011515029 A JP2011515029 A JP 2011515029A JP 2011526249 A5 JP2011526249 A5 JP 2011526249A5
Authority
JP
Japan
Prior art keywords
residues
residue
antibody
region
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011515029A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011526249A (ja
JP5701752B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2009/000869 external-priority patent/WO2010000041A1/en
Publication of JP2011526249A publication Critical patent/JP2011526249A/ja
Publication of JP2011526249A5 publication Critical patent/JP2011526249A5/ja
Application granted granted Critical
Publication of JP5701752B2 publication Critical patent/JP5701752B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011515029A 2008-07-04 2009-07-03 抗p2x7ペプチドおよびエピトープ Active JP5701752B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2008903451 2008-07-04
AU2008903451A AU2008903451A0 (en) 2008-07-04 Composite peptide
PCT/AU2009/000869 WO2010000041A1 (en) 2008-07-04 2009-07-03 Anti- p2x7 peptides and epitopes

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014222949A Division JP2015038144A (ja) 2008-07-04 2014-10-31 抗p2x7ペプチドおよびエピトープ

Publications (3)

Publication Number Publication Date
JP2011526249A JP2011526249A (ja) 2011-10-06
JP2011526249A5 true JP2011526249A5 (enExample) 2013-10-24
JP5701752B2 JP5701752B2 (ja) 2015-04-15

Family

ID=41465424

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011515029A Active JP5701752B2 (ja) 2008-07-04 2009-07-03 抗p2x7ペプチドおよびエピトープ
JP2014222949A Pending JP2015038144A (ja) 2008-07-04 2014-10-31 抗p2x7ペプチドおよびエピトープ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014222949A Pending JP2015038144A (ja) 2008-07-04 2014-10-31 抗p2x7ペプチドおよびエピトープ

Country Status (12)

Country Link
US (3) US8597643B2 (enExample)
EP (1) EP2318438B1 (enExample)
JP (2) JP5701752B2 (enExample)
KR (1) KR101701300B1 (enExample)
CN (1) CN102143978B (enExample)
AU (1) AU2009266430B2 (enExample)
BR (1) BRPI0915367B8 (enExample)
CA (1) CA2729868C (enExample)
ES (1) ES2610225T3 (enExample)
IL (2) IL210220A (enExample)
NZ (1) NZ590146A (enExample)
WO (1) WO2010000041A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100497385C (zh) 2001-01-17 2009-06-10 因特里特控股有限公司 针对非功能性p2x7受体的抗体及其在癌症和其它病情的诊断和治疗中的用途
NZ583894A (en) 2007-09-14 2013-01-25 Biosceptre Int Ltd Antibodies that bind to a non atp binding p2x7 receptor
AU2008299594B2 (en) 2007-09-14 2013-10-03 Biosceptre International Limited Purinergic (P2X) receptors in extra-cellular body fluid
WO2010000041A1 (en) 2008-07-04 2010-01-07 Biosceptre International Limiited Anti- p2x7 peptides and epitopes
ES2557456T3 (es) 2009-08-20 2016-01-26 Biosceptre (Aust) Pty Ltd Anticuerpos anti-receptor P2X7 y fragmentos de los mismos
ES2732021T3 (es) 2009-12-24 2019-11-20 Biosceptre Aust Pty Ltd Anticuerpos de receptores P2X7 oligoméricos no funcionales
WO2012031333A1 (en) 2010-09-10 2012-03-15 Biosceptre International Limited Companion animal treatments
ES2689272T3 (es) * 2011-07-01 2018-11-13 Biosceptre (Aust) Pty Ltd Terapia de combinación
CA2980788A1 (en) * 2015-04-02 2016-10-06 Biosceptre (Uk) Limited An anti-p2x7-receptor antibody for pain treatment
CN108350462B (zh) * 2015-09-11 2022-05-27 生物权威(英国)有限公司 嵌合抗原受体及其用途
US11260131B2 (en) 2016-10-21 2022-03-01 Biosceptre (Aust) Pty Ltd Cytotoxic particles for targeting P2X7 receptor
CN117157092A (zh) * 2021-04-08 2023-12-01 生物权威(澳大利亚)有限责任公司 控制免疫细胞活性的方法
WO2024055077A1 (en) * 2022-09-14 2024-03-21 Biosceptre (Aust) Pty Ltd Enrichment of engineered immune cells
EP4587464A1 (en) * 2022-09-14 2025-07-23 Biosceptre (Aust) Pty Ltd Methods of detecting immune cells
AU2023343786A1 (en) * 2022-09-14 2025-02-20 Biosceptre (Aust) Pty Ltd In vivo detection of immune cells

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE920765A1 (en) 1991-03-12 1992-09-23 Scripps Research Inst Cell surface receptors homologous to coagulation factors v¹and viii
WO1995033048A2 (en) 1994-05-27 1995-12-07 Glaxo Group Limited P2x receptors (purinoceptor family)
WO1997006256A2 (en) 1995-08-09 1997-02-20 Institut National De La Sante Et De La Recherche Medicale Isolated nucleic acid molecules useful as leukemia markers and in breast cancer prognosis
WO1997041222A1 (en) 1996-04-30 1997-11-06 Smithkline Beecham P.L.C. HUMAN P2x4 RECEPTOR SPLICE-VARIANTS
US6303338B1 (en) * 1996-08-16 2001-10-16 Human Genome Sciences, Inc. Pancreas-derived plasminogen activator inhibitor
US6306393B1 (en) * 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
JP3885177B2 (ja) 1997-03-26 2007-02-21 大塚製薬株式会社 ヒト遺伝子
US6133434A (en) * 1997-04-28 2000-10-17 Glaxo Group Limited Purinergic receptor
ES2629442T3 (es) * 1998-06-01 2017-08-09 Agensys, Inc. Nuevos antígenos transmembranales en serpentina expresados en cánceres humanos y utilizaciones de los mismos
DE19829473C2 (de) * 1998-07-01 2000-08-10 Magnus Von Knebel Doeberitz Ch Verfahren zur frühen Diagnose von Carcinomen
EP1157038A4 (en) 1999-02-26 2005-01-19 Smithkline Beecham Corp CLONING OF A P2Y-LIKE 7TM RECEPTOR (AXOR17)
AUPP991199A0 (en) * 1999-04-21 1999-05-13 University Of Sydney, The Methods for diagnosing pre-cancerous and cancerous conditions
AU1339701A (en) 1999-10-22 2001-05-08 Lifespan Biosciences, Inc. Anti-cancer nucleic acid and protein targets
AU2001274902A1 (en) * 2000-12-06 2002-06-18 Linex Technologies, Inc. Efficient sharing of capacity by remote stations using circuit switching and packet switching
AUPR201500A0 (en) * 2000-12-11 2001-01-11 Biosceptre Pty Ltd Methods for identifying pre-neoplastic and neoplastic states in mammals
CN100497385C (zh) 2001-01-17 2009-06-10 因特里特控股有限公司 针对非功能性p2x7受体的抗体及其在癌症和其它病情的诊断和治疗中的用途
TWI329648B (en) * 2001-09-03 2010-09-01 Intreat Pty Ltd Diagnosis and treatment of cancers and other conditions
WO2004092384A2 (en) 2003-04-17 2004-10-28 Affectis Pharmaceuticals Ag Means and methods for diagnosing and treating affective disorders
WO2006136004A1 (en) * 2005-05-05 2006-12-28 Medicure International Inc. Inhibition of atp-mediated, p2x7 dependent pathways by pyridoxal-5-phosphaste and vitamin b6 related compounds
US7767789B2 (en) * 2005-06-02 2010-08-03 University Hopitals of Cleveland Truncated proteins as cancer markers
EP1929305A2 (en) 2005-08-31 2008-06-11 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in leukemia signaling pathways
WO2008043146A1 (en) 2006-10-10 2008-04-17 Biosceptre International Limited Antibodies against non functional p2x7 receptor
EP2082032A4 (en) * 2006-10-10 2010-06-30 Biosceptre Int Ltd ANTIBODIES AGAINST NON-FUNCTIONAL P2X7 RECEPTOR PRODUCING HYBRIDOMES
NZ583894A (en) * 2007-09-14 2013-01-25 Biosceptre Int Ltd Antibodies that bind to a non atp binding p2x7 receptor
AU2008299594B2 (en) * 2007-09-14 2013-10-03 Biosceptre International Limited Purinergic (P2X) receptors in extra-cellular body fluid
WO2010000041A1 (en) 2008-07-04 2010-01-07 Biosceptre International Limiited Anti- p2x7 peptides and epitopes
ES2557456T3 (es) * 2009-08-20 2016-01-26 Biosceptre (Aust) Pty Ltd Anticuerpos anti-receptor P2X7 y fragmentos de los mismos
ES2732021T3 (es) 2009-12-24 2019-11-20 Biosceptre Aust Pty Ltd Anticuerpos de receptores P2X7 oligoméricos no funcionales
WO2011131472A1 (en) 2010-04-22 2011-10-27 Institut Gustave Roussy Compounds and uses thereof to induce an immunogenic cancer cell death in a subject
WO2012031333A1 (en) 2010-09-10 2012-03-15 Biosceptre International Limited Companion animal treatments
ES2689272T3 (es) 2011-07-01 2018-11-13 Biosceptre (Aust) Pty Ltd Terapia de combinación

Similar Documents

Publication Publication Date Title
JP2011526249A5 (enExample)
JP2017504578A5 (enExample)
HRP20191341T1 (hr) Protutijela koja vežu ljudski cgrp receptor
JP2019116474A5 (enExample)
JP2020508655A5 (enExample)
JP2020517287A5 (enExample)
JP2021503455A5 (enExample)
JP2020114210A5 (enExample)
JP2020524661A5 (enExample)
IL295295A (en) Antibodies against fcrl5 and methods of their use
JP2018517431A5 (enExample)
JP2009518005A5 (enExample)
US20240209082A1 (en) Anti-cd96 antibodies and methods of use thereof
JP2019504032A5 (enExample)
JP2009240323A5 (enExample)
JP2010502183A5 (enExample)
RU2016108703A (ru) Антитело, специфически связывающееся с glp-1r, и его слитый с glp-1 белок
RU2010149746A (ru) Перекрестно-реактивные антитела анти-il-17a/il-17f и способы их применения
JP2005507635A5 (enExample)
JP2017520575A5 (enExample)
JP2018509907A5 (enExample)
JP2012525829A5 (enExample)
JP2013506428A5 (enExample)
JP2012530487A5 (enExample)
NZ590146A (en) Antibodies which bind an epitope comprising two different monomers of the P2X7 receptor